•
Liver stiffness measurement by transient elastography predicts early recovery from acute hepatitismore
by Fabrizio Bronte and V. Marco
Publication Date: 2011
Publication Name: Gut
Research Interests:
•
Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis Cmore
by Fabrizio Bronte and V. Marco
Publication Date: 2011
Publication Name: American Journal of Gastroenterology
Research Interests:
•
Modified spleen stiffness measurement by transient elastography is associated with presence of large oesophageal varices in patients with compensated hepatitis C virus cirrhosismore
by Fabrizio Bronte and V. Marco
To evaluate the accuracy of liver transient elastography (TE), spleen TE and other noninvasive tests (AAR, APRI score, platelet count, platelet/spleen ratio) in predicting the presence and the size of oesophageal varices in compensated... more
To evaluate the accuracy of liver transient elastography (TE), spleen TE and other noninvasive tests (AAR, APRI score, platelet count, platelet/spleen ratio) in predicting the presence and the size of oesophageal varices in compensated hepatitis C virus (HCV) cirrhosis, we studied 112 consecutive patients with compensated HCV cirrhosis who underwent biochemical tests, gastrointestinal endoscopy, liver TE and spleen TE by Fibroscan(®) (Echosens, Paris, France) using a modified software version with a range between 1.5 and 150 kPa. Spleen TE was not reliable in 16 patients (14.3%). Among the 96 patients with a valid measurement (69.8% men, mean age: 63.2 ± 9.5 years), 43.7% had no oesophageal varices, 29.2% had grade 1% and 27.1% had grade 2 or grade 3 oesophageal varices. Patients with values of 75 kPa by standard spleen TE had mean values of modified spleen TE of 117 kPa (range: 81.7-149.5). Linear regression revealed a significant correlation between modified spleen TE and oesophageal varix size (r = 0.501; beta: 0.763, SE: 0.144; P < 0.001). On univariate analysis, the variables associated with grade 2/grade 3 oesophageal varices were AAR score, APRI score, platelet/spleen ratio, liver TE and modified spleen TE. On multivariate analysis, only modified spleen TE (OR: 1.026; 95% CI: 1.007-1.046; P = 0.006) and AAR (OR: 14.725; 95% CI: 1.928-112.459; P = 0.010) remained independently associated with grade 2/grade 3 oesophageal varices. Platelet/spleen ratio was the best predictor of oesophageal varices area under the ROC curve (AUROC: 0.763, cut-off: 800, sensitivity: 74%, specificity: 70%), while modified spleen TE was more accurate in predicting grade 2/grade 3 oesophageal varices (AUROC: 0.82, cut-off: 54.0 kPa, sensitivity: 80%, specificity: 70%). Portal hypertension increases spleen stiffness, and the measurement of modified spleen TE is an accurate, noninvasive tool for predicting the presence of large oesophageal varices in patients with compensated HCV cirrhosis.
Publication Date: 2013
Publication Name: Journal of Viral Hepatitis
Research Interests:
•
Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsymore
by Fabrizio Bronte and V. Marco
Publication Date: 2009
Publication Name: Journal of Viral Hepatitis
Research Interests:
•
Publication Date: 2007
Publication Name: Journal of Hepatology
Research Interests:
•
Publication Date: 2009
Publication Name: Journal of Hepatology
Research Interests:
•
Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis Cmore
by Fabrizio Bronte and V. Marco
Publication Date: 2012
Publication Name: Hepatology
Research Interests:
•
by Fabrizio Bronte and V. Marco
Publication Date: 2009
Publication Name: Hepatology
Research Interests: Hepatitis C, Hepatology, Multivariate Analysis, Spleen, Insulin Resistance, and 16 moreProspective studies, Humans, Portal hypertension, Liver Cirrhosis, Liver, Female, Male, Hepatitis C Virus, Risk factors, ROC Curve, Clinical Sciences, Aged, Middle Aged, Disease Progression, Risk Factors, and Platelet Count
•
Publication Date: 2012
Publication Name: Haematologica
Research Interests:
•
Publication Date: 2007
Publication Name: Gastroenterology
Research Interests:
•
by Fabrizio Bronte and V. Marco
Treatment choice for chronic HBV infection is a continuously evolving issue, with a wide range of options. We aimed to evaluate the current practice of HBV therapies in the real world in Southern Italy. A prospective study enrolling over... more
Treatment choice for chronic HBV infection is a continuously evolving issue, with a wide range of options. We aimed to evaluate the current practice of HBV therapies in the real world in Southern Italy. A prospective study enrolling over a six month period (February-July 2010) all consecutive HBsAg positive subjects, never previously treated, referred to 16 liver units in two Southern Italy regions (Calabria and Sicily). Out of 247 subjects evaluated, 116 (46.9%) had HBV-DNA undetectable or lower than 2000 UI/ml. There were 108 (43.7%) inactive carriers, 103 (41.7%) chronic hepatitis, and 36 (14.6%) liver cirrhosis. Antiviral treatment was planned in 94 (38.0%) patients (26 cases with Interferon or Pegylated Interferon and 68 with nucleos(t)ides analogues). As many as 49.5% of subjects with chronic hepatitis did not receive antiviral treatment. The majority of chronic HBsAg carrier referring centres for evaluation were not considered suitable for antiviral treatment. Nucleos(t)ides analogues are the preferred first choice for therapy. A long-lasting period of observation may be needed to make appropriate therapeutic decisions in several cases.
Publication Date: 2012
Publication Name: European Journal of Internal Medicine
Research Interests:
•
Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) â lack of interference by iron depositionmore
by Fabrizio Bronte and V. Marco
Publication Date: 2010
Publication Name: British Journal of Haematology
Research Interests:
•